Ocular Therapeutix, Inc. (OCUL)
10.36
-0.46
(-4.25%)
USD |
NASDAQ |
Aug 28, 16:00
10.36
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Cash from Operations (Quarterly) : -67.27M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -67.27M |
| March 31, 2026 | -65.99M |
| December 31, 2025 | -54.25M |
| September 30, 2025 | -50.72M |
| June 30, 2025 | -55.24M |
| March 31, 2025 | -44.67M |
| December 31, 2024 | -39.43M |
| September 30, 2024 | -36.56M |
| June 30, 2024 | -24.80M |
| March 31, 2024 | -33.89M |
| December 31, 2023 | -17.27M |
| September 30, 2023 | -12.92M |
| June 30, 2023 | -20.08M |
| March 31, 2023 | -19.97M |
| December 31, 2022 | -16.96M |
| September 30, 2022 | -13.17M |
| June 30, 2022 | -10.88M |
| March 31, 2022 | -18.60M |
| December 31, 2021 | -15.15M |
| September 30, 2021 | -12.98M |
| June 30, 2021 | -20.06M |
| March 31, 2021 | -17.36M |
| December 31, 2020 | -6.246M |
| September 30, 2020 | -13.66M |
| June 30, 2020 | -14.80M |
| Date | Value |
|---|---|
| March 31, 2020 | -18.85M |
| December 31, 2019 | -20.06M |
| September 30, 2019 | -18.95M |
| June 30, 2019 | -19.18M |
| March 31, 2019 | -19.39M |
| December 31, 2018 | -13.65M |
| September 30, 2018 | -10.87M |
| June 30, 2018 | -12.23M |
| March 31, 2018 | -12.47M |
| December 31, 2017 | -10.38M |
| September 30, 2017 | -14.38M |
| June 30, 2017 | -11.13M |
| March 31, 2017 | -14.58M |
| December 31, 2016 | -7.612M |
| September 30, 2016 | -7.331M |
| June 30, 2016 | -9.802M |
| March 31, 2016 | -9.256M |
| December 31, 2015 | -8.636M |
| September 30, 2015 | -9.70M |
| June 30, 2015 | -8.528M |
| March 31, 2015 | -6.879M |
| December 31, 2014 | -5.626M |
| September 30, 2014 | -6.333M |
| June 30, 2014 | -4.512M |
| March 31, 2014 | -4.025M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| EyePoint, Inc. | -62.35M |
| LENZ Therapeutics, Inc. | -38.71M |
| Merck & Co., Inc. | 5.37B |
| Theravance Biopharma, Inc. | -6.965M |
| ANI Pharmaceuticals, Inc. | 56.67M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.367M |
| Cash from Financing (Quarterly) | 2.581M |
| Free Cash Flow | -255.10M |
| Free Cash Flow Per Share (Quarterly) | -0.314 |
| Free Cash Flow to Equity (Quarterly) | -70.56M |
| Free Cash Flow to Firm (Quarterly) | -67.85M |
| Free Cash Flow Yield | -11.51% |